摘要
Abstract
Objective To investigate the expression and clinical significance of EBV VCA-IgA, EA-IgA and EBV-DNA in serum of patients with recurrent nasopharyngeal carcinoma. Method 120 cases with recurrent nasopharyngeal carcinoma in Cancer Hospital Chinese Academy of Medical Sciences from August 2014 to June 2016 were selected as recurrence group, and they were divided into surgery group (75 cases) and chemoradiotherapy group (45 cases) according to different treatment methods. Another 40 cases with radiation necrosis of skull base after operation were selected as non-recurrence group. The expression levels of EBV VCA-IgA、EA-IgA and EBV-DNA were analyzed among different groups. Result Before treatment, the positive rate of EBV-DNA in recurrence group was significantly higher than that in non-recurrence group (P < 0.05), while the positive rate of VCA-IgA and EA-IgA showed no significant differences between the two groups (P > 0.05). With the increase of the clinical stages, the positive rate of EBV-DNA in recurrent group was significantly increased (P<0.05), VCA-IgA and EA-IgA showed no differences among different stages (P>0.05). There were no significant differences in VCA-IgA, EBV-DNA and EA-IgA among patients with different recurrence sites (P > 0.05). The positive rate of VCA-IgA, EA-IgA and EBV-DNA showed no significant differences between surgery group and chemoradiotherapy group (P > 0.05). After treatment, the positive rate of EBV-DNA in surgery group was significantly lower than that in chemoradiotherapy group (P<0.05), and there were no differences in the positive rate of VCA-IgA and EA-IgA between the two groups (P>0.05). Conclusion EBV-DNA is helpful to the diagnosis of nasopharyngeal carcinoma recurrence and clinical staging, surgery can help to eliminate the EBV. The positive expression of EBV antibody in patients without recurrent nasopharyngeal carcinoma is high, therefore it can not be used to detect the recurrence of nasopharyngeal carcinoma.关键词
鼻咽癌/复发/EB病毒抗体/EB病毒-DNAKey words
Nasopharyngeal carcinoma/Recurrence/EBV antibody/EBV-DNA
